TNDM Price Prediction Next Week
Analysis and Insights
News and Event Impact:
- Insider Buying: Tandem Diabetes' COO purchased 10.5K shares, leading to a 2.5% increase in stock price, reaching $18.33 after hours. This indicates confidence in the company's prospects.
- Analyst Ratings: Mixed sentiment with downgrades from Morgan Stanley and Citi, lowering the price target to $22, while others see growth potential.
Technical Analysis:
- RSI (14): 27.58, suggesting oversold conditions and potential bounce.
- MACD: Negative at -4.24, indicating a bearish trend.
- Fibonacci Levels: Pivot at $19.62, resistance at $21.43, support at $17.80.
Price Prediction and Recommendation:
- Target Price: $20.50, considering potential rebound from oversold conditions and insider buying.
- Recommendation: Sell or avoid due to bearish trend and analyst downgrades.
TNDM Similar Chart Price Prediction
The price of TNDM is predicted to go up -1.57%, based on the high correlation periods with XYLO. The similarity of these two price pattern on the periods is 99.23%.
TNDM
XYLO
Down: -1.57%Similarity: 99.23%
TNDM Revenue Forecast
TNDM EPS Forecast
TNDM FAQs
What is TNDM revenue forecast for next quarter？
What is TNDM eps forecast for next quarter？
TNDM VS S&P500
Tandem's t:slim X2 features a low-profile, color touchscreen that is very user-friendly for patients new to insulin pumps.
Tandem has bulked up its product pipeline with its smaller tubed t:slim Mobi, the tubeless Mobi, and the Sigi patch pump that is tubeless and can be adhered directly onto the body.
Outside of the type 1 diabetes market, there are also significant opportunities for growth in the insulin-dependent type 2 patient pool.
TNDM Analyst's Forecast
Patrick Wood
Morgan Stanley
Buy → Hold
2025-03-05
Price Target
$45 → $22
Upside
+15.12%
Morgan Stanley downgraded Tandem Diabetes to Equal Weight from Overweight with a price target of $22, down from $45. The firm was "surprised" by Tandem's "underwhelming" guidance calling for only mid-single digit growth on the topline and in U.S. new patient shipments with seemingly very little, if any, contribution from Type 2 label expansion and pharmacy access, the analyst tells investors. It is "difficult for us to interpret the caution here as much else besides competition pressuring the outlook," the analyst added.
Joanne Wuensch
Citigroup
Strong Buy → Hold
2025-03-04
Price Target
$35 → $24
Upside
+23.14%
Larry Biegelsen
Wells Fargo
Buy → Hold
2025-03-03
Price Target
$38 → $22
Upside
+5.87%
